Abstract:[Background]Animal experimental studies have shown that arsenic exposure contributes to hepatic lipid accumulation,but epidemiological findings are inconsistent.Moreover,the role of arsenic metabolism is still unclear. [Objective]To evaluate the potential causal association between arsenic metabolism and non-alcoholic fatty liver disease(NAFLD). [Methods]A total of 1020 participants from the Dongfeng-Tongji cohort with urinary arsenic metabolites and genotype data were included in the present study(NAFLD group,n=529;non-NAFLD group,n=491).Epidemiological information was obtained by questionnaire survey,liver ultrasound was obtained by physical ex-amination,arsenic metabolites in urine were measured by high-performance liquid chromatography-inductively coupled plasma mass spectrometry,and DNA from leukocytes was extracted for genome-wide genotype.NAFLD was diagnosed if the following two criteria were met:(1)positive fatty liver according to abdominal ultrasonography;(2)excluding participants reporting history of excessive alcohol consumption(≥30 g·d-1 for men;≥20 g·d-1 for women)and/or fatty liver with other known causes.Genetic risk score(GRS)and weighted genetic risk score(w-GRS)were constructed using single nucleotide polymorphisms(SNPs)related to arsenic metabolism reported in pre-vious studies to predict the estimated arsenic metabolism.Logistic regression models were used to analyze the association between arsenic metabolism and NAFLD;linear regression models were used to analyze the association between GRS/w-GRS and arsenic metabolism,and Mendelian randomization analysis was performed using GRS method,inverse variance weighting,Egger regression,and weighted medi-an. [Results]The mean age of the 1020 participants was(68.14±7.45)years,of which 64%were female,and 529(51.9%)were NAFLD cases.The median(P25,P75)level of total arsenic in urine was 18.34(11.93,27.14)μg·L-1 with a geometric mean and standard deviation of(15.86±1.81)μg·L-1.The proportions of inorganic arsenic(iAs%),monomethylarsenic(MMA%),and dimethylarsenic(DMA%)in the total arsenic were 13.90%±9.90%,9.49%±4.97%,and 76.60%±11.00%,respectively.After adjustment for potential confounders,the ORs(95%CIs)for NAFLD risk by per standard deviation increase in iAs%and MMA%were 1.21(1.06,1.38)and 0.62(0.51,0.74)respectively.Each unit increase in GRS constructed from 77 SNPs was associated with a 0.16%increase in MMA%and a 0.19%decrease in DMA%,and each unit increase in w-GRS was associated with a 0.17%increase in MMA%and a 0.14%decrease in DMA%.After further exclusion of SNPs with linkage disequilibrium(r2>0.3)and pleiotropic effect,a total of 25 SNPs were included in the Mendelian randomization analysis.The GRS method showed that the OR(95%CI)for NAFLD risk by per unit increase in MMA%expectation was 0.95(0.90,0.99),and the inverse variance weighting method also showed a significant association between MMA%and NAFLD,with OR(95%CI)of 0.91(0.84,0.99). [Conclusion]There is a negative causal association between MMA%and NAFLD.

Integrated miRNA-mRNA analysis reveals the dysregulation of lipid metabolism in mouse liver induced by developmental arsenic exposure

Aberrant Hepatic Microrna Expression in Nonalcoholic Fatty Liver Disease

Arsenic exposure at environmentally relevant levels induced metabolic toxicity in development mice: Mechanistic insights from integrated transcriptome and metabolome

As3MT via consuming SAM is involved in arsenic-induced nonalcoholic fatty liver disease by blocking m6A-mediated miR-142-5p maturation

DNA hydroxymethylation reprogramming of -oxidation genes mediates early-life arsenic-evoked hepatic lipid accumulation in adult mice

Long-term arsenic exposure decreases mice body weight and liver lipid droplets

Developmental Arsenic Exposure Induces Dysbiosis of Gut Microbiota and Disruption of Plasma Metabolites in Mice.

Effects of Early Life Oral Arsenic Exposure on Intestinal Tract Development and Lipid Homeostasis in Neonatal Mice: Implications for NAFLD Development

Hepatic Transcriptomic Responses in Mice Exposed to Arsenic and Different Fat Diet

Integrated metabolomics and network pharmacology revealing the mechanism of arsenic-induced hepatotoxicity in mice

Mechanism underlying the targeted regulation of the SOD1 3′UTR by the AUF1/Dicer1/miR-155/SOD1 pathway in sodium arsenite-induced liver injury

Integration of Transcriptomic and Metabolomic Data to Compare the Hepatotoxicity of Neonatal and Adult Mice Exposed to Aristolochic Acid I

LC/MS/MS-Based Liver Metabolomics to Identify Chronic Liver Injury Biomarkers Following Exposure to Arsenic in Rats

Functional metabolomics reveals arsenic-induced inhibition of linoleic acid metabolism in mice kidney in drinking water

Causal Association Between Arsenic Metabolism and Non-Alcoholic Fatty Liver Disease Based on Mendelian Randomization

microRNA-21, via the HIF-1/VEGF signaling pathway, is involved in arsenite-induced hepatic fibrosis through aberrant cross-talk of hepatocytes and hepatic stellate cells

Disruption of the Mouse Liver Epitranscriptome by Long-term Aroclor 1260 Exposure

Non-coding RNA therapeutics: Towards a new candidate for arsenic-induced liver disease

Altered Expression Profiles of Micrornas Upon Arsenic Exposure of Human Umbilical Vein Endothelial Cells.

Associations of Arsenic Exposure and Arsenic Metabolism with the Risk of Non-Alcoholic Fatty Liver Disease.

Effects of dietary arsenic exposure on liver metabolism in mice